History
A list of downloadable documents created during development.
Review proposal consultation
Background information
-
Psoriatic arthritis - golimumab: review proposal - June 2013 information
-
TA220 Psoriatic arthritis - golimumab: Appendix A provisional matrix of stakeholders
-
TA220 Psoriatic arthritis - golimumab: Appendix A provisional matrix of stakeholders (PDF 39 KB)
-
TA220 Psoriatic arthritis - golimumab: Appendix B - proposal paper presented to the Institute's Guidance Executive
-
Psoriatic arthritis - golimumab: EIA form
-
Psoriatic arthritis - golimumab: EIA form
-
Psoriatic arthritis - golimumab: final appraisal determination
-
Psoriatic arthritis - golimumab: final appraisal determination information
-
Psoriatic arthritis - golimumab: final appraisal determination document
-
Psoriatic arthritis - golimumab: final appraisal determination document (PDF 232 KB)
-
Psoriatic arthritis - golimumab: response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Psoriatic arthritis - golimumab: consultee and commentator comments on the ACD
-
Psoriatic arthritis - golimumab: Merck Sharp & Dohme (formerly Schering-Plough)
-
Psoriatic arthritis - golimumab: Merck Sharp & Dohme (formerly Schering-Plough) (PDF 1.17 MB)
-
Psoriatic arthritis - golimumab: Psoriasis and Psoriatic Arthritis Alliance
-
Psoriatic arthritis - golimumab: Psoriasis and Psoriatic Arthritis Alliance (PDF 134 KB)
-
Psoriatic arthritis - golimumab: Psoriasis Association
-
Psoriatic arthritis - golimumab: Psoriasis Association (PDF 167 KB)
-
Psoriatic arthritis - golimumab: British Association of Dermatologists (endorsed by Royal College of Physicians)
-
-
Psoriatic arthritis - golimumab: British Health Professionals in Rheumatology
-
Psoriatic arthritis - golimumab: British Health Professionals in Rheumatology (PDF 189 KB)
-
Psoriatic arthritis - golimumab: British Society for Rheumatology (endorsed by Royal College of Physicians)
-
-
Psoriatic arthritis - golimumab: Royal College of Nursing
-
Psoriatic arthritis - golimumab: Royal College of Nursing (PDF 59 KB)
-
Psoriatic arthritis - golimumab: Royal College of Pathologists
-
Psoriatic arthritis - golimumab: Royal College of Pathologists (PDF 37 KB)
-
Psoriatic arthritis - golimumab: Abbott
-
-
Psoriatic arthritis - golimumab: expert comments on the ACD
-
Psoriatic arthritis - golimumab: Sue Ashwell, NHS commissioning expert nominated by NHS Cambridgeshire on behalf of NHS Havering
-
-
Psoriatic arthritis - golimumab: web comments on the ACD
-
Psoriatic arthritis - golimumab: web comments on the ACD (PDF 49 KB)
-
Psoriatic arthritis - golimumab: Manufacturer response to request for additional information from Merck Sharp & Dohme (formerly Schering-Plough)
-
Psoriatic arthritis - golimumab: appraisal consultation
-
Psoriatic arthritis - golimumab: appraisal consultation
-
Psoriatic arthritis - golimumab: appraisal consultation document information
-
Psoriatic arthritis - golimumab: evaluation report
-
Psoriatic arthritis - golimumab: pre-meeting briefing
-
Psoriatic arthritis - golimumab: pre-meeting briefing (PDF 451 KB)
-
Psoriatic arthritis - golimumab: Evidence Review Group report
-
Psoriatic arthritis - golimumab: Evidence Review Group report (PDF 748 KB)
-
Psoriatic arthritis - golimumab: manufacturer submission
-
Psoriatic arthritis - golimumab: manufacturer submission (PDF 2.84 MB)
-
Psoriatic arthritis - golimumab: NICE clarification letter
-
Psoriatic arthritis - golimumab: NICE clarification letter (PDF 98 KB)
-
Psoriatic arthritis - golimumab: manufacturer response to clarification letter
-
Psoriatic arthritis - golimumab: manufacturer response to clarification letter (PDF 863 KB)
-
Psoriatic arthritis - golimumab: non-manufacturer submissions
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - Psoriasis and Psoriatic Arthritis Alliance
-
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - British Association of Dermatologists (endorsed by Royal College of Physicians)
-
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - British Health Professionals in Rheumatology
-
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - British Society for Rheumatology
-
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - Primary Care Rheumatology Society
-
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - Royal College of Pathologists
-
-
Psoriatic arthritis - golimumab: non-manufacturer submissions - NHS Cambridgeshire on behalf of NHS Havering
-
-
Psoriatic arthritis - golimumab: expert written personal statements
-
Psoriatic arthritis - golimumab: expert written personal statements - Anstey
-
Psoriatic arthritis - golimumab: expert written personal statements - Anstey (PDF 19 KB)
-
Psoriatic arthritis - golimumab: expert written personal statements - Ashwell
-
Psoriatic arthritis - golimumab: expert written personal statements - Ashwell (PDF 7.8 KB)
-
Psoriatic arthritis - golimumab: expert written personal statements - Helliwell
-
Psoriatic arthritis - golimumab: expert written personal statements - Helliwell (PDF 78 KB)
-
Psoriatic arthritis - golimumab: expert written personal statements - James
-
Psoriatic arthritis - golimumab: expert written personal statements - James (PDF 161 KB)
-
Psoriatic arthritis - golimumab: expert written personal statements - Korendowych
-
Psoriatic arthritis - golimumab: expert written personal statements - Korendowych (PDF 14 KB)
Psoriatic arthritis - golimumab: final matrix
-
Psoriatic arthritis - golimumab: final matrix
-
Psoriatic arthritis - golimumab: final scope
-
Psoriatic arthritis - golimumab: final scope
-